STAT+: Chasing CAR-T, biotech finds its next gold rush in autoimmune disease
STAT
OCTOBER 14, 2024
Companies that are developing new medicines for autoimmune conditions, as well as other immune system disorders, have brought in more money and closed more deals so far this year than most other areas, including the cardiometabolic field, data from investment bank Oppenheimer show. Continue to STAT+ to read the full story…
Let's personalize your content